Related Experiment Videos
Treatment of perioperative low cardiac output syndrome
A R Doyle1, A K Dhir, A H Moors
1Department of Anaesthesia, Papworth Hospital, Cambridgeshire, England.
Abstract:
New approaches to the treatment of perioperative low cardiac output are considered. In particular, use of the phosphodiesterase III inhibitors and their cardiovascular actions are reviewed and contrasted with those of conventional inotropic agents. The increasing recognition of right-sided dysfunction is highlighted, and appropriate therapeutic strategies are considered. The increasing role of pulmonary-specific vasodilators such as inhaled nitric oxide is emphasized. Strategies to preserve right heart perfusion while producing pulmonary vasodilatation are discussed.
Insights
New treatments for perioperative low cardiac output focus on phosphodiesterase III inhibitors and managing right-sided heart dysfunction. Strategies include using inhaled nitric oxide for pulmonary vasodilation while preserving right heart function.
Area of Science:
- Cardiology
- Anesthesiology
- Pharmacology
Background:
- Perioperative low cardiac output is a significant clinical challenge.
- Conventional inotropic agents have limitations in managing this condition.
- Increasing recognition of right-sided heart dysfunction necessitates tailored therapeutic approaches.
Purpose of the Study:
- To review novel treatment strategies for perioperative low cardiac output.
- To contrast phosphodiesterase III inhibitors with traditional inotropic agents.
- To discuss management of right-sided dysfunction and pulmonary vasodilation.
Main Methods:
- Review of current literature on phosphodiesterase III inhibitors.
- Analysis of cardiovascular actions of novel therapeutic agents.
- Discussion of clinical strategies for right heart dysfunction and pulmonary hypertension.
Main Results:
- Phosphodiesterase III inhibitors offer an alternative to conventional inotropic agents.
- Inhaled nitric oxide is a key pulmonary-specific vasodilator.
- Balancing right heart perfusion with pulmonary vasodilation is crucial.
Conclusions:
- Novel pharmacologic agents and strategies are emerging for perioperative low cardiac output.
- Management of right-sided heart dysfunction and pulmonary vasodilation requires specific attention.
- Optimizing treatment involves preserving right heart function while improving pulmonary circulation.